EQS Group-Media / 2020-06-30 / 21:00
*Media Release *
*Medacta Announces First Hip Replacement Surgeries with New Quadra-P System
Following Successful FDA Clearance and CE Marking *
_CASTEL SAN PIETRO, 30 June 2020_ - Medacta announced today the first
surgeries in the U.S. and Europe with its new Quadra-P Collared and Quadra-P
Cemented femoral stems following recent clearance from the U.S. Food and
Drug Administration (FDA) and CE marking in Europe.
These new stem options follow the successful release of Medacta's Quadra-P
hip prosthesis in 2019 and together, complete the Quadra-P Hip System, a
complete system of stems for use in hip replacement surgery. The first
Quadra-P Cemented stem was implanted on March 4, 2020 by Thomas McCoy, M.D.,
in Leesburg, Florida (U.S.), while the first surgeries utilizing the
Quadra-P Collared stem were performed on May 25, 2020 by Dr. Med. Panayiotis
Christofilopoulos in Geneva, Switzerland, and May 26, 2020 by Peter Thadani,
M.D., in Chicago (U.S.).
Quadra-P is part of the Medacta Family of P-Stems, along with AMIStem-P and
SMS. The tapered rectangular stems all feature proximal coating and
progressive neck lengths, with a range of stem lengths and canal filling
dimensions that give clinicians the ability to match an implant to the
patient's bone morphology.
"Stem selection is a critical component to positive patient outcomes, and
the P-Stem Family affords our surgeons the ability to select a distally
reduced, collarless, collared or cemented stem that best matches their
patient's femoral bone morphology and bone quality," said Francesco
Siccardi, CEO of Medacta. "With this broader range of innovative stem
options, we are able to provide surgeons with an enhanced complete system
for total hip arthroplasty that better meets the needs of a wide range of
patients."
The Quadra-P System is the evolution of the original Quadra-H System, the
first stem Medacta developed, which features a remarkable clinical heritage
of more than 15 years, outstanding survival rates (99.6% at 10 years) and
thousands of stems implanted worldwide each year.
In alignment with Medacta's mission to transform the patient experience by
advancing solutions through responsible innovation, the Quadra-P System has
been enhanced with MectaGrip, Medacta's state-of-the-art proximal coating;
progressive head center growth that more closely reflects the patient's
natural anatomy; and a collared option that further expands the system's
offerings.
"Medacta has built upon the excellent long-term results of its fully
HA-coated femoral stems by adding a proximal MectaGrip coating to the
Quadra-P stem system," said John Masonis, M.D., of OrthoCarolina Hip & Knee
Center in Charlotte, North Carolina (U.S.), one of the Quadra-P designers.
"The MectaGrip coating allows for more proximal load transfer and provides a
mechanically stronger bone-to-implant interface. The single system expands
on the proven stability of the cementless Quadra by adding the cementless
with collar and updated cemented options. This gives me and other surgeons a
stem system that can address different femoral bone morphologies among a
varying patient population."
The MectaGrip coating is designed for enhanced initial stability and
long-term fixation to satisfy higher demands of younger, more active
patients who put more stress on their implants. The anatomical head center
growth makes the Quadra-P System particularly suitable to more efficiently
restore the native hip joint biomechanics in a larger population.
The Quadra-P System also provides the utmost in intraoperative flexibility
as a collarless, collared or cemented stem, as all options use a single
instrument platform, potentially increasing operating room efficiency and
streamlining processes for surgeons and health systems.
For more information on the Quadra-P System, visit
https://www.medacta.com/EN/quadra-p-system-global [1].
*Contact*
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch
*About Medacta*
Medacta is an international company specialized in the design and production
of innovative orthopaedic products and the development of accompanying
surgical techniques for joint replacement, spine surgery, and sports
medicine. Established in 1999 in Switzerland, Medacta's products and
surgical techniques are characterized by innovation. Medacta is a pioneer in
developing new offerings on the basis of minimally invasive surgical
techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS")
technique for hip replacements. Medacta has leveraged its orthopaedic
expertise and comprehensive understanding of the human body to develop the
sophisticated "MySolutions" technology, which offers surgeons highly
personalized pre-operative planning and implant placement methodologies by
creating advanced personalized kinematic models and 3D planning tools for
use in hip, knee, shoulder and spine procedures.
Issuer: Medacta Group SA
Key word(s): Research/Technology
End of Corporate News
Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1083057
End of News EQS Group Media
1083057 2020-06-30
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=0266d0660666e5f6432f3ebd2055691f&application_id=1083057&site_id=vwd&application_name=news
(END) Dow Jones Newswires
June 30, 2020 15:00 ET (19:00 GMT)
